Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:BLTENASDAQ:CGONNASDAQ:GLPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$5.22+1.0%$3.99$1.42▼$5.98$460.15M0.881.08 million shs3.32 million shsBLTEBelite Bio$60.48+0.2%$61.42$43.70▼$86.53$1.92B-1.4447,119 shs83,537 shsCGONCG Oncology$25.55-2.8%$24.87$14.80▼$40.47$2.00B0.86842,217 shs987,475 shsGLPGGalapagos$27.42-2.8%$27.23$22.36▼$31.23N/A0.07249,328 shs322,509 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+0.97%+0.38%+39.20%+41.85%+521,999,900.00%BLTEBelite Bio+0.20%+1.56%-10.12%-10.11%+21.81%CGONCG Oncology-2.78%-1.20%-2.56%-5.55%-24.61%GLPGGalapagos-2.83%-4.66%-5.42%+6.20%+6.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRaTyr Pharma2.4955 of 5 stars3.61.00.00.03.51.70.6BLTEBelite Bio2.8392 of 5 stars3.53.00.00.03.80.80.6CGONCG Oncology2.2235 of 5 stars4.51.00.00.01.90.80.0GLPGGalapagos0.1938 of 5 stars0.82.00.00.01.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 3.14Buy$20.20286.97% UpsideBLTEBelite Bio 3.00Buy$96.6759.83% UpsideCGONCG Oncology 3.00Buy$58.67129.62% UpsideGLPGGalapagos 1.50Reduce$25.33-7.61% DownsideCurrent Analyst Ratings BreakdownLatest ATYR, CGON, BLTE, and GLPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.006/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$52.00 ➝ $56.006/4/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.005/19/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/19/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/2/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.004/29/2025CGONCG OncologyRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.004/28/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$75.00 ➝ $75.004/28/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$230K2,019.91N/AN/A$0.83 per share6.29BLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/ACGONCG Oncology$1.14M1,708.26N/AN/A$9.63 per share2.65GLPGGalapagos$298.31MN/A$0.71 per share38.87$47.57 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$64.02M-$0.81N/AN/AN/AN/A-87.09%-64.77%8/12/2025 (Estimated)BLTEBelite Bio-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)CGONCG Oncology-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)Latest ATYR, CGON, BLTE, and GLPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CGONCG Oncology-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million5/7/2025Q1 2025ATYRaTyr Pharma-$0.19-$0.17+$0.02-$0.17N/AN/A4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr Pharma0.017.797.79BLTEBelite BioN/A24.3124.31CGONCG OncologyN/A30.9730.97GLPGGalapagosN/A7.957.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%BLTEBelite Bio0.53%CGONCG Oncology26.56%GLPGGalapagos32.46%Insider OwnershipCompanyInsider OwnershipATYRaTyr Pharma3.70%BLTEBelite Bio13.29%CGONCG Oncology7.40%GLPGGalapagos2.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5389.00 million85.71 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableCGONCG Oncology6176.22 million70.58 millionOptionableGLPGGalapagos1,310N/AN/AOptionableATYR, CGON, BLTE, and GLPG HeadlinesRecent News About These CompaniesGalapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity ...June 20 at 7:32 PM | manilatimes.netGalapagos Unveils Promising Results for GLPG5101 at ICML 2025June 20 at 4:43 PM | tipranks.comGalapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101June 18 at 4:01 PM | globenewswire.comOwning 37% shares,institutional owners seem interested in Galapagos NV (AMS:GLPG),June 17, 2025 | uk.finance.yahoo.comGalapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHLJune 12, 2025 | globenewswire.comGalapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Reduce" by BrokeragesJune 12, 2025 | marketbeat.comGalapagos NV (NASDAQ:GLPG) Shares Sold by Millennium Management LLCJune 5, 2025 | marketbeat.comAmeriprise Financial Inc. Decreases Holdings in Galapagos NV (NASDAQ:GLPG)June 1, 2025 | marketbeat.comDelivering CAR T-Cell Therapies Faster Than Ever BeforeMay 30, 2025 | usatoday.comWealthedge Investment Advisors LLC Acquires New Holdings in Galapagos NV (NASDAQ:GLPG)May 30, 2025 | marketbeat.comGalapagos NV: Galapagos Creates New Subscription Right PlanMay 27, 2025 | finanznachrichten.deGalapagos Creates New Subscription Right PlanMay 27, 2025 | globenewswire.comWoodline Partners LP Purchases Shares of 45,899 Galapagos NV (NASDAQ:GLPG)May 27, 2025 | marketbeat.comGalapagos Reaches Analyst Target PriceMay 23, 2025 | nasdaq.comGalapagos Announces Oral Presentations at EHA and…May 20, 2025 | pharmiweb.comGalapagos to reevaluate spinoff plans; names new CEOMay 13, 2025 | msn.comGalapagos halts corporate separation, explores strategic alternatives; shares riseMay 13, 2025 | ca.investing.comPharma group Galapagos picks new CEO, backtracks on spinoffMay 13, 2025 | msn.comGalapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board ChangesMay 13, 2025 | globenewswire.comGalapagos NV Announces Key Resolutions from Annual Shareholders’ MeetingApril 29, 2025 | tipranks.comRBC Capital Sticks to Their Hold Rating for Galapagos (GLPG)April 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATYR, CGON, BLTE, and GLPG Company DescriptionsaTyr Pharma NASDAQ:ATYR$5.22 +0.05 (+0.97%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.26 +0.04 (+0.86%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Belite Bio NASDAQ:BLTE$60.48 +0.12 (+0.20%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$60.50 +0.02 (+0.02%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.CG Oncology NASDAQ:CGON$25.55 -0.73 (-2.78%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$25.54 -0.02 (-0.06%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Galapagos NASDAQ:GLPG$27.42 -0.80 (-2.83%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$27.42 0.00 (0.00%) As of 06/20/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
